key: cord-0838223-dqootl7o
authors: Cheng, Annie; Riedel, Stefan; Arnaout, Ramy; Kirby, James E.
title: Verification of the Abbott Alinity m Resp-4-Plex Assay for detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus
date: 2021-10-22
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2021.115575
sha: 705af1ac462a855ebb8ff1ff9d6f82dfa0019653
doc_id: 838223
cord_uid: dqootl7o

COVID-19 symptomology may overlap with other circulating respiratory viruses that may also cause severe disease and for which there are specific and potentially life-saving treatments. The Abbott Alinity m Resp-4-Plex assay is a multiplex PCR assay that simultaneously detects and differentiates infection with SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV). We characterized its accuracy, precision, and analytical sensitivity. All were found to be robust for measures examined. In the context of sample-to-answer, near random access automation on the Alinity m platform, we believe that the Resp-4-Plex assay offers significant utility in addressing the current needs of the SARS-CoV-2 pandemic and future needs during anticipated endemic circulation of SARS-CoV-2 with other respiratory viruses.

SARS-CoV-2, influenza A/B, and RSV may cause respiratory infection with significant morbidity and mortality. Respiratory disease signs and symptoms for these viruses overlap, and, therefore, it is not possible to reliably differentiate between them on clinical grounds alone, especially early during the course of disease. SARS-CoV-2 and influenza, especially, have significant implications in terms of transmission inside and outside of hospital settings and therefore require reliable methods for diagnosis. RSV, although primarily thought of as a serious pathogen in young children, can also cause bronchiolitis and pneumonia in adults. Depending on the stage of illness, there are therapeutics with varying efficacy for SARS-CoV-2, influenza, and RSV. Therefore, sensitive detection and differentiation of these viruses are valuable clinical determinations.

With social distancing and masking during the COVID pandemic, the circulation of influenza and other respiratory viruses almost ceased in many locations (Olsen, et al., 2020) .

Presumably, however, with less than 100% vaccine efficacy for influenza, waning immunity to circulating respiratory viruses over a large population cohort, and reopening of society, circulation of influenza and RSV may rebound and even exceed normal levels for a period of time (Baker, et al., 2020) . At the same time, SARS-CoV-2 will likely become endemic, potentially adopting a seasonal cycle with enhanced transmission during the winter, as observed in the United States during the winters of 2020 and 2021 (Byun, et al., 2021) . It will therefore be critical to be able to test both patients and symptomatic staff for high consequence respiratory pathogens to avert potential nosocomial transmission and to identify the most advantageous therapeutic options for patients with serious illness.

A multiplex testing option for high-consequence testing would address these specific diagnostic needs. The Abbott Alinity m Resp-4-Plex assay in March 2021 received emergency use authorization designation for detection of SARS-CoV-2, influenza A, influenza B and RSV.

Approved sample types are either a nasopharyngeal swab collected by a health care provider or a nasal swab specimen self-collected in a healthcare setting submitted in viral transport medium or saline. The multiplex, reverse-transcription real-time PCR assay targets the RdRp and N genes of SARS-CoV2: the matrix gene of influenza A; the nonstructural 1 gene of influenza B, and the matrix gene of RSV. An internal control is spiked into each sample in the form of armored RNA encoding a segment of the hydroxypyruvate reductase gene from the pumpkin plant, Cucurbita pepo; it controls for appropriate extraction and amplification in each reaction. Each amplicon is detected by a real-time probe with a distinct fluorophore with the exception that probes for both SARS-CoV-2 targets are detected with the same fluorophore. The primers and probes for the SARS-CoV-2 targets are the same as those used in the singleplex Abbott RealTime SARS-CoV-2 and Alinity m SARS-CoV-2 assays, whose performance characteristics have been examined in prior literature (Arnaout, et al., 2021; Hirschhorn, et al., 2021; Smith, et al., 2020) . Cycle threshold numbers (Ct) determined on the Alinity m instrument in the Resp-4-Plex assay are determined based on a fluorescence cutoff. They are used along with the inflection point of the amplification curve at the maximum amplification efficiency (the max ratio) (Shain & Clemens, 2008) for qualitative assessment of target positivity and negativity (personal communication, Joshua Kostera, Abbott Molecular).

Here we describe characterization of accuracy, precision, and limit of detection of the Alinity m Resp-4-Plex assay determined as part of normal quality assurance activities prior to adoption for clinical use in our clinical laboratory.

Patients and samples. Samples tested were nasopharyngeal flocked swab samples transported in universal transport medium (for all samples other than those initially tested for SARS-CoV-2) or saline (for SARS-CoV-2 comparisons). Specimens were collected from an almost exclusively adult population with an average age of 54 years (S.D. +/-21 years). There was no pre-selection of patients based on demographics or sex; however, on later analysis it was found that there was a skew to higher female samples represented (64% female, 36% male). All but one specimen selected based on comparator positivity for influenza A and B were obtained from the 2019-2020 winter influenza season. SARS-CoV-2 positive specimens were from January 2021 or earlier. Negative specimens were from 2020 and 2021. Specimens positive for respiratory viruses other than those detected in the Resp-4-Plex assay were obtained during the years 2015-2021. Specimens were stored for less than 72 hours at 4°C prior to initial testing and then frozen at -80°C. Samples went through a total of two freeze-thaw cycles during the process of aliquoting for this study. Samples were maintained frozen at -80°C until the day of testing by Resp-4-Plex and supplementary methods.

Results from prior determinations either by Cepheid Xpert® Xpress Flu; direct fluorescent antigen testing for influenza A/B, RSV, adenovirus, and parainfluenza 1, 2 and 3 and/or detection in shell vial culture on R-Mix-Too monolayers (Quidel Corporation, San Diego, CA) were performed using the D3 Ultra DFA Respiratory Screening and Identification Kit, (Quidel) and/or reference laboratory testing at Eurofin ViraCor using the laboratory-developed TEM-PCR assay (Han, et al., 2006) were considered predicate comparator assays as enumerated. Samples were divided for Resp-4-Plex testing on the two Alinity m instruments at our institution. As there was no difference in performance on these identical systems, results are presented in aggregate. Discrepant resolution included repeat testing of samples as available using Resp-4-Plex on the second Alinity m platform and/or using the Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV assay. Data for individual sample is listed in Table S1 . on Ct values obtained from each screening concentration, and PCR efficiency was determined using slope of the regression line using the ThermoFisher calculator: https://www.thermofisher.com/us/en/home/brands/thermo-scientific/molecularbiology/molecular-biology-learning-center/molecular-biology-resource-library/thermoscientific-web-tools/qpcr-efficiency-calculator.html. Three dilutions bracketing the potential limit of detection cutoff were tested again with twenty replicates each to establish the LoD for each analyte. The 95% detection threshold and confidence intervals were extrapolated by logistic regression in Prism 9 for MacOS (GraphPad, San Diego, CA). LoD analysis was performed on a single Alinity m instrument.

To determine accuracy, the Resp-4-Plex assay was run using clinical samples that were previously determined to be positive for the constituent viruses. Ten samples previously determined to be SARS-CoV-2 positive using the Alinity m SARS-CoV-2 singleplex assay were tested using Resp-4-Plex. All were positive for SARS-CoV-2. Although the Ct values for SARS-CoV-2 on Resp-4-Plex were a mean -1.81 +/-0.58 lower than fractional cycle numbers on the singleplex assay, the assays were highly correlated with one another (R 2 = 0.99) ( Fig   1A) .

Flu were tested using Resp-4-Plex. All tested positive for influenza A. A single sample tested with Resp-4-Plex also yielded a positive RSV result with a high Ct value of 32.46 (see limit of detection analysis below). The test was repeated using Resp-4-Plex on the second Alinity m instrument and gave qualitatively and quantitatively almost identical results. The sample was then tested using the Cepheid Xpress SARS-CoV-2/Flu/RSV assay and was influenza A positive, RSV negative. The latter result could therefore either represent an Xpress RSV false negative based on low viral load or a Resp-4-Plex false positive.

Ten samples previously determined to be influenza B positive using the Cepheid Xpress Flu assay were tested using Resp-4-Plex. All tested positive for influenza B. A single sample tested with Resp-4-Plex also yield a positive RSV result. The test was repeated using Resp-4-Plex on the second Alinity m instrument and gave similar results. The sample was then tested using the Cepheid Xpress SARS-CoV-2/Flu/RSV assay and was influenza B positive, RSV positive. This sample was resolved as an influenza B/RSV true positive.

Ten samples previously determined to be RSV positive using a combination of direct fluorescence antigen testing and/or shell vial culture and a single sample determined to be RSV positive by TEM-PCR were tested using Resp-4-Plex. All were positive for RSV.

Eighteen samples previously determined to be negative for viruses by direct fluorescent antigen testing and/or shell vial culture, five of which were also negative by TEM-PCR, were 

For SARS-CoV-2, the LoD screen demonstrated excellent linearity with R 2 = 0.98 and a 97% PCR efficiency (Fig. 1B) . The manufacturer's claimed LoD was confirmed through twenty replicates at 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 100% and 80% detection, respectively. The LoD was therefore <= 25 copies per mL with an Ct value of 35.72 +/-0.54 at 25 copies/mL. The logistic regression was non-convergent and therefore an extrapolated LoD could not be established.

For influenza A, the LoD screen demonstrated excellent linearity with R 2 = 0.97 and 93% PCR efficiency. The manufacturer's claimed LoD was confirmed through twenty replicates at 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 80% and 30% detection, respectively. The LoD was therefore <= to 50 copies per mL with an Ct value of 37.18 +/-0.67 at 50 copies/mL. By logistic regression, the LoD was 47 copies/mL (95% confidence interval ~25-125 copies/mL).

For influenza B, the LoD screen demonstrated excellent linearity with an R 2 = 0.97 and a 101% PCR efficiency. The manufacturer's claimed LoD was confirmed through twenty replicates at 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 90% and 70% detection, respectively. The LoD was therefore <= to 50 copies per mL with an Ct value of 35.94+/-0.73 at 50 copies/mL. By logistic regression, the LoD was 36 copies/mL (95% confidence interval ~18-178 copies/mL).

For RSV, the LoD screen demonstrated excellent linearity with an R 2 = 0.97 and 97% PCR efficiency. The manufacturer's claimed LoD was confirmed through twenty replicates at 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 90% and 75% detection, respectively. The LoD was <= to 50 copies per mL with an Ct value of 35.75 +/-0.70 at 50 copies/mL. By logistic regression the LoD was 39.8 copies/mL (95% confidence interval ~18-1000 copies/mL).

Intra-run precision was determined by using pooled samples, positive for each of the four viruses, and a negative pool. Each pool was tested in quadruplicate on each of the two Alinity m instruments with each individual test for each specific virus performed on each of the Assay Processing Units (APU) #1 through #4 on each instrument, so that every APU was tested during precision testing. Inter-run precision was verified by testing the pools for each virus on each alinity m instrument again on an additional two separate days. Qualitative intra-run and inter-run precision results were 100% correlated, as expected.

Although Resp-4-Plex is a qualitative assay, we also assessed quantitative precision by comparison of Ct values in replicates. Coefficients of variation (CV) varied from 0.6 to 2.5% across all viruses tested on both instruments in intra-run precision comparisons and from 0.4% to 2.9% in inter-run precision comparisons. The precision of the Ct values for positive controls run during the validation on Alinity m #1 (n=4) and Alinity m #2 (n=5) instruments, run once per day of testing, was also examined. CVs on individual instruments for each assay were all less than 1%. There was no statistical difference between the positive control Ct values run on Alinity #1 and Alinity #2 for the four viruses (Fig. 1C) , with significance considered P <= 0.05, with comparisons performed using the Kruskall-Wallis test. Therefore, reproducibility of both instruments appeared essentially identical for the Resp-4-Plex assay.

The Resp-4-Plex assay is welcome addition to targeted respiratory panel options that will be necessary in a post-COVID world. It appeared highly accurate, sensitive, and precise.

The three discrepancies with original comparator methods, specifically detection of coinfections, could be attributed to enhanced detection by Resp-4-Plex. This was because: (1) the second virus was detected on repeat testing by Resp-4-Plex on a second Alinity m platform, (2) the second virus was detected by the alternative Cepheid respiratory panel, and/or (3) the second virus had a very high Ct value, near its limit of detection, and therefore plausibly may have been below the limit of detection of the comparator assays. Coinfections with influenza and RSV are relatively rare, but their detection in our study may reflect the overlapping seasonality during sample collection periods and/or high acuity of patients (Hardick, et al., 2021) . Overall, our experience was consistent with qualitative detection data described in the EUA product insert, although our data set was significantly smaller in size.

Notably, the LoD for each individual virus was robust with high amplification efficiencies even in the context of a multiplex assay and testing of quality control material in which all four targets were present in equivalent amounts. The multiplex and singleplex SARS-CoV-2 assays were also extremely well correlated (R 2 = 0.99). Furthermore, the Ct values were also log-linearly correlated with the quantitative standard at and above the limit of detection of the assays with excellent PCR efficiencies. The log-linear performance of the Resp-4-Plex assays suggest that future conversion to a quantitative readout, i.e., a viral load, should easily be supported (Arnaout, et al., 2021) and under certain circumstances may provide additional utility for patient management.

Several limitations of the study should be noted. The number of samples examined were relatively small, limiting the power of the study. Several comparator assays were used based on our current clinical practice. Furthermore, samples were frozen between initial testing by the comparator and later testing using the Resp-4-Plex method. It is possible that storage and freeze-thaw may have resulted in specimen degradation, although we did not observe lower detection using the Resp-4-Plex method relative to comparators.

Taken together, we verified the performance characteristics of a new multiplex respiratory panel assay on the Alinity m molecular system. This platform notably provides high throughput, sample-to-answer, random access and semi-batch functionality with a 115-minute sample-to-answer turnaround time for prioritized specimens; and an ability to load and perform multiple different tests at the same time. We believe this assay and platform will be especially useful in fulfilling future needs in situations where SARS-CoV-2, influenza A, influenza B and RSV circulate at significant levels and where these viruses need to be detected and differentiated for optimal patient management. (Shain & Clemens, 2008) from the Alinity m SARS-CoV-2 singleplex assay were highly correlated when testing patient samples spanning the analytical measurement range of these tests. Ct values for each individual assay in Resp-4-Plex, tested on four to five separate days on two separate Alinity instruments, were highly correlated and not statistically (n.s.) different between instruments.

JE (2021) The Limit of Detection Matters: The Case for Benchmarking Severe Acute Respiratory Syndrome Coronavirus 2 Testing

BT (2020) The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections

JH (2021) Is coronavirus disease (COVID-19) seasonal? A critical analysis of empirical and epidemiological studies at global and local scales

Simultaneous Amplification and Identification of 25 Human Papillomavirus Types with Templex Technology

RE (2021) Identification of pathogens from the upper respiratory tract of adult emergency department patients at high risk for influenza complications in a pre-Sars-CoV-2 environment

FS (2021) Verification and Validation of SARS-CoV-2 Assay Performance on the Abbott m2000 and Alinity m Systems

AM (2020) Decreased Influenza Activity During the COVID-19 Pandemic -United States

A new method for robust quantitative and qualitative analysis of real-time PCR

Large-Scale, In-House Production of Viral Transport Media To Support SARS-CoV-2 PCR Testing in a Multihospital Health Care Network during the COVID-19 Pandemic

We thank the Abbott Molecular Group for providing test reagents and LGC SeraCare control